Clinical Trial Update: Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 study of TAK-228 (sapanisertib) in patients with previously treated metastatic renal cell carcinoma has completed, with results posted in February 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• TAK-228

Snippet

Sponsor: Bradley A. McGregor, MD | Conditions: Renal Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2022-02-24